Mechanisms underlying the antiproliferative effects of a series of quinoxaline-derived chalcones
The present study aimed to characterize the effects of quinoxaline-derived chalcones, designed on the basis of the selective PI3Kγ inhibitor AS605240, in oral cancer cells. Three lead compounds, namely N9, N17 and N23, were selected from a series of 20 quinoxaline-derived chalcones, based on an initial screening using human and rat squamous cell carcinoma lineages, representing compounds with at least one methoxy radical at the A-ring. The selected chalcones, mainly N9 and N17, displayed marked antiproliferative effects, via apoptosis and autophagy induction, with an increase of sub-G1 population and Akt inhibition. The three chalcones displayed marked in vitro antitumor effects in different protocols with standard chemotherapy drugs, with acceptable toxicity on normal cells. There was no growth retrieval, after exposure to chalcone N9 alone, in a long-term assay to determine the cumulative population doubling (CPD) of human oral cancer cells. A PCR array evaluating 168 genes related to cancer and inflammation, demonstrated striking actions for N9, which altered the expression of 74 genes. Altogether, our results point out quinoxalinic chalcones, mainly N9, as potential strategies for oral cancer treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Scientific reports - 7(2017), 1 vom: 20. Nov., Seite 15850 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mielcke, Tânia R [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.07.2019 Date Revised 10.12.2019 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-017-16199-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM278246982 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM278246982 | ||
| 003 | DE-627 | ||
| 005 | 20231226194521.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-017-16199-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0927.xml |
| 035 | |a (DE-627)NLM278246982 | ||
| 035 | |a (NLM)29158524 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mielcke, Tânia R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mechanisms underlying the antiproliferative effects of a series of quinoxaline-derived chalcones |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.07.2019 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The present study aimed to characterize the effects of quinoxaline-derived chalcones, designed on the basis of the selective PI3Kγ inhibitor AS605240, in oral cancer cells. Three lead compounds, namely N9, N17 and N23, were selected from a series of 20 quinoxaline-derived chalcones, based on an initial screening using human and rat squamous cell carcinoma lineages, representing compounds with at least one methoxy radical at the A-ring. The selected chalcones, mainly N9 and N17, displayed marked antiproliferative effects, via apoptosis and autophagy induction, with an increase of sub-G1 population and Akt inhibition. The three chalcones displayed marked in vitro antitumor effects in different protocols with standard chemotherapy drugs, with acceptable toxicity on normal cells. There was no growth retrieval, after exposure to chalcone N9 alone, in a long-term assay to determine the cumulative population doubling (CPD) of human oral cancer cells. A PCR array evaluating 168 genes related to cancer and inflammation, demonstrated striking actions for N9, which altered the expression of 74 genes. Altogether, our results point out quinoxalinic chalcones, mainly N9, as potential strategies for oral cancer treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a 5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione |2 NLM | |
| 650 | 7 | |a Chalcones |2 NLM | |
| 650 | 7 | |a Neoplasm Proteins |2 NLM | |
| 650 | 7 | |a Phosphoinositide-3 Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Quinoxalines |2 NLM | |
| 650 | 7 | |a Thiazolidinediones |2 NLM | |
| 650 | 7 | |a Class Ib Phosphatidylinositol 3-Kinase |2 NLM | |
| 650 | 7 | |a EC 2.7.1.137 |2 NLM | |
| 650 | 7 | |a PIK3CG protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.1.137 |2 NLM | |
| 700 | 1 | |a Muradás, Thaís C |e verfasserin |4 aut | |
| 700 | 1 | |a Filippi-Chiela, Eduardo C |e verfasserin |4 aut | |
| 700 | 1 | |a Amaral, Maria Eduarda A |e verfasserin |4 aut | |
| 700 | 1 | |a Kist, Luiza W |e verfasserin |4 aut | |
| 700 | 1 | |a Bogo, Maurício R |e verfasserin |4 aut | |
| 700 | 1 | |a Mascarello, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Neuenfeldt, Patrícia D |e verfasserin |4 aut | |
| 700 | 1 | |a Nunes, Ricardo J |e verfasserin |4 aut | |
| 700 | 1 | |a Campos, Maria M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 7(2017), 1 vom: 20. Nov., Seite 15850 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2017 |g number:1 |g day:20 |g month:11 |g pages:15850 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-017-16199-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2017 |e 1 |b 20 |c 11 |h 15850 | ||